Long-term Factors in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Author Information
Author(s): E Brain, C Garrino, J-L Misset, I Garcia Carbonero, M ltzhaki, E Cvitkovic, E Goldschmidt, F Burki, C Regensberg, E Pappo, R Hagipantelli, M Musset
Primary Institution: Hôpital Paul Brousse
Hypothesis
The study aims to identify predictive and prognostic factors in breast cancer patients treated with neoadjuvant chemotherapy.
Conclusion
The study found that pathological evaluation of antitumoral activity is crucial for prognostic information in breast cancer patients treated with neoadjuvant chemotherapy.
Supporting Evidence
- Median disease-free survival was 90.5 months.
- Clinical response rates were 87% based on clinical evaluation.
- Pathological complete response was associated with better outcomes.
Takeaway
Doctors wanted to see what helps predict how well treatment works for women with breast cancer who got chemotherapy before surgery. They found that looking at the tumor after treatment gives important clues.
Methodology
The study analyzed 107 women with stage II/III non-inflammatory breast carcinoma treated with anthracycline-based neoadjuvant chemotherapy followed by surgery, using univariate and multivariate analyses.
Potential Biases
Potential biases due to the retrospective nature and single-center design of the study.
Limitations
The study is retrospective and may not account for all variables affecting outcomes.
Participant Demographics
The study included 107 women with a median age of 52 years, with both premenopausal and post-menopausal participants.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website